Format

Send to

Choose Destination
Front Microbiol. 2017 Feb 27;8:293. doi: 10.3389/fmicb.2017.00293. eCollection 2017.

A Novel Antimicrobial Endolysin, LysPA26, against Pseudomonas aeruginosa.

Author information

1
Department of Microbiology and Immunology, Institutes of Medical Science, Shanghai Jiao Tong University School of Medicine Shanghai, China.
2
Department of Clinical Medicine, Hangzhou Medical College Hangzhou, China.

Abstract

The global increase in multidrug resistant (MDR) bacteria has led to phage therapy being refocused upon. A novel endolysin, LysPA26, containing a lysozyme-like domain, was screened against Pseudomonas aeruginosa in this study. It had activity against MDR P. aeruginosa without pretreatment with an outer-membrane permeabilizer. LysPA26 could kill up to 4 log units P. aeruginosa in 30 min. In addition, temperature and pH effect assays revealed that LysPA26 had good stability over a broad range of pH and temperatures. Moreover, LysPA26 could kill other Gram-negative bacteria, such as Klebsiella pneumonia, Acinetobacter baumannii and Escherichia coli, but not Gram-positive bacteria. Furthermore, LysPA26 could eliminate P. aeruginosa in biofilm formation. Our current results show that LysPA26 is a new and promising antimicrobial agent for the combat of Gram-negative pathogens.

KEYWORDS:

LysPA26; Pseudomonas aeruginosa; antimicrobial agent; bacteriophage; endolysin

Supplemental Content

Full text links

Icon for Frontiers Media SA Icon for PubMed Central
Loading ...
Support Center